Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/17/2025 | $6.00 | Sell | Citigroup |
2/28/2025 | $19.00 | Buy | BTIG Research |
7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan |
5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities |
5/10/2024 | Underweight → Neutral | JP Morgan | |
8/9/2023 | $15.00 | Neutral → Buy | B. Riley Securities |
4/20/2023 | $55.00 → $10.00 | Outperform → Market Perform | TD Cowen |
3/1/2023 | $29.00 → $10.00 | Buy → Neutral | B. Riley Securities |
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
Both vaccine candidates induced robust immune responses across all antigens testedNo new safety signals were observed and both vaccine candidates were well tolerated consistent with past trialsNovavax continues to pursue partnering opportunities to advance further development of these programsGAITHERSBURG, Md., June 11, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid® and Fluzone HD, respective
GAITHERSBURG, Md., May 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside Chat Date: Wednesday, June 4, 2025 Time: 2:00 – 2:30 p.m. Eastern Time (ET) Location: New York, NY Goldman Sachs 46th Annual Global Healthcare Conference: Presentation Date: Wednesday, June 11, 2025 Time: 2:00 – 2:35 p.m. ET Location: Miami Beach, FL A webcast of the fireside chat and presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcasts will be available for 30 days. About NovavaxNovavax, I
Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earnedGAITHERSBURG, Md., May 19, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years